| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
1 Vaccine Branch and 2 Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
Requests for reprints: Masaki Terabe, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 10/Room 6B12, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-435-8349; Fax: 301-402-0549; E-mail: terabe{at}mail.nih.gov or Chand Khanna, Tumor and Metastasis Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9610 Medical Center Drive, Rm 315, Key West Medical Center, Rockville, MD 20850. Phone: 301-594-3406; Fax: 301-402-4422; E-mail: khannac{at}mail.nih.gov.
It has been shown previously that the suppression of tumor immunosurveillance may be a mechanism by which tumors resist immune detection and elimination. In this study, we evaluated the role of the immunoregulatory natural killer T (NKT) cells in the biology of immunosurveillance of osteosarcoma. The K7M2 mouse osteosarcoma cell line was implanted orthotopically into wild-type and NKT celldeficient CD1d knockout (KO) BALB/c mice, and mice were monitored for growth of primary tumors. Further, we examined the role of CD4+ and/or CD8+ cells by depleting the cells in vivo and measuring CTL activity in vitro. We also asked the role of interleukin (IL)-4 receptor
(IL-4R
)-signal transducer and activator of transcription 6 (STAT6) signaling, including IL-13, and transforming growth factor ß (TGF-ß) by using gene-disrupted mice or treating mice with cytokine antagonists. We were surprised to find a high rate of rejection of osteosarcoma primary tumors in 88% (14 of 16) of CD1d KO mice compared with syngeneic wild-type BALB/c mice that showed rejection of tumor in <24% of mice. Further studies suggested that the rejection of tumor in CD1d KO mice was dependent on CD8+ lymphocytes. Distinct from other murine tumor models, the negative regulation induced by CD1d-restricted NKT cells was not dependent on IL-4R
-STAT6 signaling, including IL-13, or on TGF-ß. These data suggest that a novel CD1d-restricted NKT cellmediated mechanism for tumor immunosuppression is active in the K7M2 osteosarcoma model and that NKT cells can regulate immunosurveillance through more than one pathway. (Cancer Res 2006; 66(7): 3869-75)
This article has been cited by other articles:
![]() |
M. W. L. Teng, S. Yue, J. Sharkey, M. A. Exley, and M. J. Smyth CD1d Activation and Blockade: A New Antitumor Strategy J. Immunol., March 15, 2009; 182(6): 3366 - 3371. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Ko, J.-M. Lee, Y.-J. Kim, Y.-S. Kim, K.-A Lee, and C.-Y. Kang Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine J. Immunol., February 15, 2009; 182(4): 1818 - 1828. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Pilones, N. Kawashima, A. M. Yang, J. S. Babb, S. C. Formenti, and S. Demaria Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade Clin. Cancer Res., January 15, 2009; 15(2): 597 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Berzofsky and M. Terabe NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis J. Immunol., March 15, 2008; 180(6): 3627 - 3635. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yoshimura, L. S. Laird, C. Y. Chia, K. F. Meckel, J. E. Slansky, J. M. Thompson, A. Jain, D. M. Pardoll, and R. D. Schulick Live Attenuated Listeria Monocytogenes Effectively Treats Hepatic Colorectal Cancer Metastases and Is Strongly Enhanced by Depletion of Regulatory T Cells Cancer Res., October 15, 2007; 67(20): 10058 - 10066. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ambrosino, M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis J. Immunol., October 15, 2007; 179(8): 5126 - 5136. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |